India based pharma major - Orchid Chemicals and Pharmaceuticals has received approvals from FDA for its ANDAs for Piperacillin and Tazobactam. These are available in both vial and Bulk Dosage forms. Orchid is the "first applicant" and a 180day generic drug exclusivity was granted by FDA. The Indian firm has marketing and distribution partnership with Apotex a US based company. Speaking at a conference, Mr K Raghavendra Rao, Managing Director, Orchid said, “This is a great milestone in our US Generics journey. We are not only the first generic product to be approved but also have been granted 180-days generic drug exclusivity. These approvals demonstrate Orchid’s world-class technological and regulatory skills. Given the premium nature of this life-saving antibiotic and our first generic status with exclusivity, we anticipate significant contribution to our revenues and profitability from this product in the ensuing quarters.”
Anyways, this is a good start from our side..These sort of improvements in the near future helps us to raise our global image..

Reference:
Biospectrum - Business Of Life Sciences.